



## Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026.

### Jefferies Global Healthcare Conference

**1x1 Meetings:** June 3<sup>rd</sup> and 4<sup>th</sup>

**Presentation Date & Time:** June 3<sup>rd</sup>, 2026, at 5:30PM – 6:00PM ET

**Location:** New York, NY

**Webcast registration link:** <https://event.summitcast.com/view/NgCqua4VVQig9ibVWHVWca/8dAzVtF9jmoLFUYwXokBzq>

If you are interested in meeting with the Eupraxia team during the conference, please contact your Jefferies representative.

### About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: [www.eupraxiapharma.com](http://www.eupraxiapharma.com).

### For investor and media inquiries, please contact:

James Meikle, Eupraxia Pharmaceuticals Inc.

236.330.7084

[jmeikle@eupraxiapharma.com](mailto:jmeikle@eupraxiapharma.com)

or

Kevin Gardner, on behalf of:

Eupraxia Pharmaceuticals Inc.

617.283.2856

[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

SOURCE Eupraxia Pharmaceuticals Inc.